Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Intervalo de año de publicación
1.
Braz J Med Biol Res ; 53(1): e9001, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31939598

RESUMEN

Due to its various structures in bio-compounds, snake venom is the indisputable result of evolutionary stages of molecules with an increasingly complex structure, high specificity, and of great importance for medicine because of their potential. The present study proposed an underpinning examination of venom composition from nine species of venomous snakes using a useful and replicable methodology. The objective was the extension of the evaluation of protein fractions in the field up to 230 kDa to permit possible identification of some fractions that are insufficiently studied. The gel capillary electrophoresis method on the chip was performed using an Agilent 2100 bioassay with the 80 and 230-LabChip Protein kits. Interpretation of electrophoresis was performed using the Protein 2100 expert (Agilent) test software as follows: a) Protein 80 (peak size scale): 1.60, 3.5, 6.50, 15.00, 28.00, 46.00, 63.00, 95.00 kDa; b) Protein 230 (peak size scale): 4.50, 7.00, 15.00, 28.00, 46.00, 63.00, 95.00, 150.00, 240.00 kDa. The screening revealed the presence of compounds with a molecular weight greater than 80 kDa, in the case of Vipera aspis and Vipera xantina palestinae. For V. aspis, a 125 kDa molecular weight pro-coagulant protein was identified, known as being involved in the reduction of plasma clotting time without any direct activity in the fibrinogen coagulation process. The samples examined on the Protein 230-LabChip electrophoresis chip can be considered as a novelty with possible uses in medicine, requiring further approaches by advanced proteomics techniques to confirm the intimate structural features and biological properties of snake venoms.


Asunto(s)
Proteínas/química , Venenos de Víboras/química , Viperidae/clasificación , Animales , Electroforesis Capilar , Proteínas/análisis , Proteínas/aislamiento & purificación , Proteoma/química , Proteoma/clasificación , Proteómica/métodos , Venenos de Víboras/análisis
2.
Braz. j. med. biol. res ; 53(1): e9001, Jan. 2020. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1055477

RESUMEN

Due to its various structures in bio-compounds, snake venom is the indisputable result of evolutionary stages of molecules with an increasingly complex structure, high specificity, and of great importance for medicine because of their potential. The present study proposed an underpinning examination of venom composition from nine species of venomous snakes using a useful and replicable methodology. The objective was the extension of the evaluation of protein fractions in the field up to 230 kDa to permit possible identification of some fractions that are insufficiently studied. The gel capillary electrophoresis method on the chip was performed using an Agilent 2100 bioassay with the 80 and 230-LabChip Protein kits. Interpretation of electrophoresis was performed using the Protein 2100 expert (Agilent) test software as follows: a) Protein 80 (peak size scale): 1.60, 3.5, 6.50, 15.00, 28.00, 46.00, 63.00, 95.00 kDa; b) Protein 230 (peak size scale): 4.50, 7.00, 15.00, 28.00, 46.00, 63.00, 95.00, 150.00, 240.00 kDa. The screening revealed the presence of compounds with a molecular weight greater than 80 kDa, in the case of Vipera aspis and Vipera xantina palestinae. For V. aspis, a 125 kDa molecular weight pro-coagulant protein was identified, known as being involved in the reduction of plasma clotting time without any direct activity in the fibrinogen coagulation process. The samples examined on the Protein 230-LabChip electrophoresis chip can be considered as a novelty with possible uses in medicine, requiring further approaches by advanced proteomics techniques to confirm the intimate structural features and biological properties of snake venoms.


Asunto(s)
Animales , Venenos de Víboras/química , Proteínas/química , Viperidae/clasificación , Venenos de Víboras/análisis , Proteínas/aislamiento & purificación , Proteínas/análisis , Electroforesis Capilar , Proteoma/clasificación , Proteoma/química , Proteómica/métodos
3.
Acta Vet Hung ; 55(3): 287-94, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17867455

RESUMEN

The effect of two nonsteroidal anti-inflammatory drugs (carprofen and ketoprofen) on platelet adhesion and aggregation functions was evaluated by the PFA-100 analyser (Dade-Behring, CA, U.S.A.) using its collagen-adenosine diphosphate (ADP) and collagen-epinephrine (EPI) cartridges. The function of platelets was evaluated in 55 healthy dogs, in 7 dogs treated with ketoprofen and in 31 dogs treated with carprofen in a therapeutic dose for minimum 5 days. The therapeutic doses of carprofen had no effect on the closure time of PFA-100 (which is the marker of platelet function) but ketoprofen caused a significant increase when using collagen-EPI stimulation The closure times for both the healthy (control) and the treated dogs using EPI cartridges were often longer than the upper default cut-off point (300 sec) of the device. The PFA-100 analyser with collagen-ADP cartridges could be a useful tool for veterinary applications including the evaluation of platelet aggregation in dogs treated with NSAIDs. The upper cut-off point of PFA-100 might be extended.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Plaquetas/fisiología , Carbazoles/farmacología , Perros/sangre , Cetoprofeno/farmacología , Agregación Plaquetaria/efectos de los fármacos , Animales , Plaquetas/efectos de los fármacos , Femenino , Masculino , Agregación Plaquetaria/fisiología , Pruebas de Función Plaquetaria/instrumentación , Pruebas de Función Plaquetaria/métodos , Pruebas de Función Plaquetaria/veterinaria
4.
Z Rheumatol ; 37(1-2): 51-5, 1978.
Artículo en Alemán | MEDLINE | ID: mdl-629096

RESUMEN

The influence of D-Penicillamine on protein synthesis in synovial fluid cells was investigated in 5 patients suffering from rheumatoid arthritis. Intra-articular injection of this substance at a dosage of 5 to 250 mg is followed by an inhibition of protein synthesis in the synovial fluid cells.


Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Penicilamina/uso terapéutico , Biosíntesis de Proteínas , Líquido Sinovial/citología , Enfermedad Crónica , Depresión Química , Humanos , Articulación de la Rodilla , Penicilamina/farmacología , Líquido Sinovial/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...